MX2022005292A - Metodos de tratamiento con anticuerpos contra bcma y cd3. - Google Patents

Metodos de tratamiento con anticuerpos contra bcma y cd3.

Info

Publication number
MX2022005292A
MX2022005292A MX2022005292A MX2022005292A MX2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A MX 2022005292 A MX2022005292 A MX 2022005292A
Authority
MX
Mexico
Prior art keywords
methods
bcma
treatment
antibodies against
against bcma
Prior art date
Application number
MX2022005292A
Other languages
English (en)
Spanish (es)
Inventor
Michael Burgess
Minh Diem Vu
Kristen Hege
Kaushik Datta
Isaac Boss
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022005292A publication Critical patent/MX2022005292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022005292A 2019-11-05 2020-11-04 Metodos de tratamiento con anticuerpos contra bcma y cd3. MX2022005292A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP20179573 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
MX2022005292A true MX2022005292A (es) 2022-08-10

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005292A MX2022005292A (es) 2019-11-05 2020-11-04 Metodos de tratamiento con anticuerpos contra bcma y cd3.

Country Status (11)

Country Link
US (1) US20230057602A1 (enExample)
EP (1) EP4054725A4 (enExample)
JP (1) JP7792333B2 (enExample)
KR (1) KR20220093141A (enExample)
CN (1) CN115279459A (enExample)
AU (1) AU2020379757A1 (enExample)
BR (1) BR112022008516A2 (enExample)
CA (1) CA3160137A1 (enExample)
IL (1) IL292704A (enExample)
MX (1) MX2022005292A (enExample)
WO (1) WO2021092056A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
WO2025042742A1 (en) * 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
EP3535295A1 (en) * 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
KR20190074300A (ko) * 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약

Also Published As

Publication number Publication date
AU2020379757A1 (en) 2022-05-26
US20230057602A1 (en) 2023-02-23
WO2021092056A1 (en) 2021-05-14
JP7792333B2 (ja) 2025-12-25
EP4054725A1 (en) 2022-09-14
KR20220093141A (ko) 2022-07-05
CA3160137A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
EP4054725A4 (en) 2024-01-10
JP2022553822A (ja) 2022-12-26
IL292704A (en) 2022-07-01
BR112022008516A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
BR112022008516A2 (pt) Métodos de tratamento com anticorpos contra bcma e cd3
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
PE20190392A1 (es) Antianticuerpos gprc5d, moleculas de union al antigeno biespecificas que se unen a gprc5d y cd3, y usos de estas
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
MX2019010156A (es) Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
NI201800057A (es) Anticuerpos anti-il1rap, moléculas de unión de antígeno biespecíficas que se unen a il1rap y cd3, y sus usos.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
NI201700025A (es) Agentes de unión a cd123 y usos de estos.
MX375746B (es) Combinación de lenalidomida y constructo de polipéptido, y sus usos.
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
MX2018012468A (es) Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
MX2017001031A (es) Móleculas de unión a her2 y cd3 biespecíficas.
CO2018001621A2 (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
MY202368A (en) Methods of treating ulcerative colitis
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX392014B (es) Composiciones y métodos para modular la expresión de angiotensinógeno.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2025003354A (es) Anticuerpos que se unen a 5t4